FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510132174> ?p ?o ?g. }

• W2510132174 endingPage "58482" @default.
• W2510132174 startingPage "58470" @default.
• W2510132174 abstract "// Yang Song 1, * , Bing Sun 2, * , LiHong Hao 1 , Jun Hu 1 , Sha Du 3 , Xin Zhou 1 , LiYuan Zhang 1 , Lu Liu 1 , LinLin Gong 1 , XinMing Chi 1 , Qiang Liu 3 , ShuJuan Shao 1, 4 1 Department of Histology and Embryology, Dalian Medical University, Dalian, China 2 Department of Chest Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China 3 Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, Liaoning, China 4 Liaoning Key Laboratory of Proteomics, Dalian Medical University, Liaoning, China * These authors have contributed equally to this work Correspondence to: Shujuan Shao, email: shaoshujuan2006@126.com Keywords: eukaryotic elongation factor 2, lung squamous cell carcinoma, proliferation, invasion, proteomics Received: March 16, 2016     Accepted: July 27, 2016     Published: August 16, 2016 ABSTRACT Eukaryotic elongation factor 2 (EF2), is a critical enzyme solely responsible for catalyzing the translocation of the elongated peptidyl-tRNA from the A to P sites of the ribosome during the process of protein synthesis. EF2 is found to be highly expressed in a variety of malignant tumors and is correlated with cancer cell progression and recurrence. The present study was designed to uncover the function of EF2 on lung squamous cell carcinoma (LSCC) cancer cell growth and progression. Our results from clinical tissue studies showed that EF2 protein was significantly overexpressed in LSCC tissues, compared with the adjacent normal lung tissues, which was confirmed by western blotting and tissue microarray. Forced expression of EF2 resulted in the enhancement of lung squamous carcinoma NCI-H520 cells growth through promotion of G2/M progression in cell cycle, activating Akt and Cdc2/Cyclin B1. In nude mice cancer xenograft model, overexpression of EF2 significantly facilitated cell proliferation in vivo. Furthermore, forced expression of EF2 in the cells increased the capabilities of migration and invasion by changing the expressions of EMT-related proteins and genes. These results provided novel insights into the role of EF2 in tumorigenesis and progression in LSCC. EF2-targeted therapy could become a good strategy for the clinical treatment of LSCC." @default.
• W2510132174 created "2016-09-16" @default.
• W2510132174 creator A5007141142 @default.
• W2510132174 creator A5008736880 @default.
• W2510132174 creator A5009094942 @default.
• W2510132174 creator A5011689931 @default.
• W2510132174 creator A5016009303 @default.
• W2510132174 creator A5027781871 @default.
• W2510132174 creator A5029316081 @default.
• W2510132174 creator A5029397237 @default.
• W2510132174 creator A5049264813 @default.
• W2510132174 creator A5059519440 @default.
• W2510132174 creator A5068315400 @default.
• W2510132174 creator A5068691811 @default.
• W2510132174 date "2016-08-16" @default.
• W2510132174 modified "2023-10-17" @default.
• W2510132174 title "Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma" @default.
• W2510132174 cites W1525867888 @default.
• W2510132174 cites W1560901632 @default.
• W2510132174 cites W1964825240 @default.
• W2510132174 cites W1975209526 @default.
• W2510132174 cites W1976767543 @default.
• W2510132174 cites W1981243923 @default.
• W2510132174 cites W1984277720 @default.
• W2510132174 cites W1992828394 @default.
• W2510132174 cites W2002191689 @default.
• W2510132174 cites W2002205753 @default.
• W2510132174 cites W2007154778 @default.
• W2510132174 cites W2014424166 @default.
• W2510132174 cites W2018556770 @default.
• W2510132174 cites W2026347977 @default.
• W2510132174 cites W2028117656 @default.
• W2510132174 cites W2032232569 @default.
• W2510132174 cites W2032263421 @default.
• W2510132174 cites W2037313242 @default.
• W2510132174 cites W2047800844 @default.
• W2510132174 cites W2050159286 @default.
• W2510132174 cites W2060354323 @default.
• W2510132174 cites W2075981998 @default.
• W2510132174 cites W2086524655 @default.
• W2510132174 cites W2092246783 @default.
• W2510132174 cites W2093821311 @default.
• W2510132174 cites W2098598082 @default.
• W2510132174 cites W2098600956 @default.
• W2510132174 cites W2106016335 @default.
• W2510132174 cites W2117962623 @default.
• W2510132174 cites W2127764461 @default.
• W2510132174 cites W2136950355 @default.
• W2510132174 cites W2136979907 @default.
• W2510132174 cites W2148135345 @default.
• W2510132174 cites W2158046302 @default.
• W2510132174 cites W2162151227 @default.
• W2510132174 cites W2172298521 @default.
• W2510132174 cites W2409928242 @default.
• W2510132174 cites W39874842 @default.
• W2510132174 doi "https://doi.org/10.18632/oncotarget.11298" @default.
• W2510132174 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5295444" @default.
• W2510132174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27542262" @default.
• W2510132174 hasPublicationYear "2016" @default.
• W2510132174 type Work @default.
• W2510132174 sameAs 2510132174 @default.
• W2510132174 citedByCount "11" @default.
• W2510132174 countsByYear W25101321742017 @default.
• W2510132174 countsByYear W25101321742018 @default.
• W2510132174 countsByYear W25101321742019 @default.
• W2510132174 countsByYear W25101321742020 @default.
• W2510132174 countsByYear W25101321742021 @default.
• W2510132174 countsByYear W25101321742022 @default.
• W2510132174 countsByYear W25101321742023 @default.
• W2510132174 crossrefType "journal-article" @default.
• W2510132174 hasAuthorship W2510132174A5007141142 @default.
• W2510132174 hasAuthorship W2510132174A5008736880 @default.
• W2510132174 hasAuthorship W2510132174A5009094942 @default.
• W2510132174 hasAuthorship W2510132174A5011689931 @default.
• W2510132174 hasAuthorship W2510132174A5016009303 @default.
• W2510132174 hasAuthorship W2510132174A5027781871 @default.
• W2510132174 hasAuthorship W2510132174A5029316081 @default.
• W2510132174 hasAuthorship W2510132174A5029397237 @default.
• W2510132174 hasAuthorship W2510132174A5049264813 @default.
• W2510132174 hasAuthorship W2510132174A5059519440 @default.
• W2510132174 hasAuthorship W2510132174A5068315400 @default.
• W2510132174 hasAuthorship W2510132174A5068691811 @default.
• W2510132174 hasBestOaLocation W25101321741 @default.
• W2510132174 hasConcept C104317684 @default.
• W2510132174 hasConcept C121608353 @default.
• W2510132174 hasConcept C126322002 @default.
• W2510132174 hasConcept C139124968 @default.
• W2510132174 hasConcept C142724271 @default.
• W2510132174 hasConcept C2776256026 @default.
• W2510132174 hasConcept C502942594 @default.
• W2510132174 hasConcept C54355233 @default.
• W2510132174 hasConcept C62112901 @default.
• W2510132174 hasConcept C67705224 @default.
• W2510132174 hasConcept C71924100 @default.
• W2510132174 hasConcept C75186080 @default.
• W2510132174 hasConcept C86803240 @default.
• W2510132174 hasConcept C88478588 @default.
• W2510132174 hasConceptScore W2510132174C104317684 @default.

• next